Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3)
NCT ID: NCT04990856
Last Updated: 2021-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
28 participants
INTERVENTIONAL
2021-08-10
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise in Triple- Negative Breast Cancer
NCT06672120
Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients
NCT03860740
Exercise Controls Tumor Cell Growth Through AMPK Activation
NCT01376583
Consequences of Eccentric Cycling on Exercise-related Neuromuscular Responses and Biomarkers in Breast Cancer Patients
NCT05166148
Lymphatic Response to Resistance Exercise in Breast Cancer Survivors
NCT06113627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES AND PURPOSE
The most important objective of this directly translatable and highly inter- disciplinary imaging, physical activity, health and medical research in the acute exercise study setting is:
To investigate whether acute moderate intensity exercise increases tumor blood flow
-It is hypothesized and expected that exercise increases tumor blood flow, documented as perfusion increase after acute exercise
STUDY DESIGN Each subject will serve their own control (tumor blood flow at rest vs. blood flow after exercise). Tumor blood flow will be measured with positron emission tomography (PET). To study the effect of acute physical exercise on tumor blood flow and its heterogeneity, bicycle exercise before PET scan will be used to exercise breast cancer and lymphoma cancer patients. These experiments are additional measurements to their normal treatments, and no new interventional approaches will be conducted in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental arm
Blood flow of the tumor experimented
Exercise
Tumor blood flow after acute exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
Tumor blood flow after acute exercise
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ilkka Heinonen
Adj. prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ilkka Heinonen
Role: PRINCIPAL_INVESTIGATOR
Turku PET Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku PET Centre
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T06/024/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.